Researchers at the University of Oxford have begun the most recent circular of tests for their COVID-19 vaccine in the United States, a step in the race to defeat the coronavirus pandemic.
Oxford researchers, in partnership with AstraZeneca, began administering the dose to the first volunteers in Florida on Friday, and 31 Americans received the vaccine or placebo over the weekend as a component of the clinical trial.
“Look at the number of lives lost. And I just don’t need it to continue,” said Jacob Serrano, 23, a trial volunteer, Dr. Jon LaPook, a leading medical collaborator at cbs News.
As the first American to get the vaccine or his placebo from Oxford and AstraZeneca, Serrano has already lost seven members of his circle of relatives to COVID-19 and says he should be part of the life-saving solution, no matter what.
“I know there was a threat because it’s like, it’s an attempt,” Serrano said.”But I would approach, no matter what it takes.
In the third and final phase, the protection and efficacy of the vaccine to lessen or block symptoms of COVID-19 is tested, and approved for public use by the Food and Drug Administration.
Serrano ran Friday, August 28 at the Headlands Jem Research Institute in Lake Worth, Florida.Larry Bush, an infectious disease expert and lead researcher at the site, said he was positive about the effectiveness of the vaccine.
“The immune reaction is very encouraging,” he said.
In the first stage and at the time of trials, Bush said the vaccine had shown that “not only do you get physically powerful neutralizing antibodies to fight coronavirus, but you get a reaction from the matrix of T cells … to fight the cells that are infected. very important in the remedy of infections “.
T cells are “another arm of the immune system” that can fight the virus, Bush said.
The University of Oxford has conducted phase 3 trials in the UK, Brazil and South Africa.In earlier stages, there is no evidence that the vaccine caused serious reactions.
Headlands Research said its purpose is to recruit members of black and Latino communities who were disproportionately affected by the pandemic.
“The figures imply that these teams of people (…) they swelled at a higher rate,” Bush said.”As a result, this is an organization that would gain great benefits from vaccination.”
AstraZeneca has announced plans to recruit up to 50,000 participants internationally and plans to launch Phase 3 trials in Japan and Russia.The pharmaceutical giant expects to have complex effects later in 2020.